Join us on the latest episode! Our Guest: Javier Swarcberg, CEO of Spruce Biosciences

What you'll get out of this episode:

Dive deep into the world of Congenital Adrenal Hyperplasia (CAH) treatments and drug development.
Understand the challenges and rewards of addressing rare diseases, especially in pediatrics.
Javier Szwarcberg discusses Spruce's innovative Tildesophon and its potential impact on the CAH therapeutic landscape.
Discover the upcoming clinical updates from Spruce Biosciences and the promising future outlook for CH treatments.

To learn more about Spruce Biosciences: https://sprucebio.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

Corrales Cachola: This Is How You Define Your Web3 Mission, Vision And Values On The Human Blockchain